Druggable oncogene-driven non-small cell lung cancer has led to innovative systemic treatment options, improving patients' outcome. This benefit is not only achieved in the metastatic setting but also in the postsurgical setting, such as in lung cancers harboring a common sensitizing EGFR mutation or...
The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use...
Additionally, the review explores the dual nature of ferroptosis in lung cancer progression, which presents interesting therapeutic possibilities. On one hand, ferroptosis can promote the escape of immune surveillance and reduce the efficacy of treatment in the early stages of ...
“When lung cancer is diagnosed at an early stage, surgery is often the first treatment. As the characteristic of lung cancer has many recurrences after surgery, however, we have always researched whether it is possible to reduce the probability of recurrence,” said Professor Cho Jang-ho of t...
Immune checkpoint inhibitors (ICIs), programmed cell death protein-1/ligand-1 (PD-1/PD-L1) inhibitors and to a lesser extent cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockers, have proven to be an effective strategy in the treatment of lung cancer, NSCLC and small cell lung ca...
Bevacizumab/Chemo Combination Approved for Treating Metastatic Colorectal Cancer The HPV Vaccine: A Model of Research and Prevention Topotecan Gets Expanded Indication for Combined Therapy of Cervical Cancer Protein-Bound Paclitaxel Promising as First-Line Treatment in Non-Small-Cell Lung Cancer ...
To detail the proposed skills and roles of an onco-pulmonologist. Lung cancer remains the leading cause of cancer-related death in the USA, and it requires
with six achieving a complete response. In the otherstudy, researchers at the University of Pennsylvania gave a combination therapy to patients with metastatic non-small cell lung cancer as a first-line treatment. Typically, the response rate of these patients to Keytruda alone is about 45%, but...
In a survey looking at 115 countries, the WHO also found a majority of nations don't spend enough on cancer care and treatment. "This is not the time to turn away. It's the time to double down and make those investments in cancer prevention and control," said Dr. Andre IIbawi...
AI's Role in Differentiating MDS and Pre-MDS at ASH 2024 Exciting Advances in AML Treatment: Jain on Key Highlights for ASH 2024 A Step Forward in c-Met-Targeted Therapy in NSCLC c-Met as a Biomarker in Gastric/GEJ Cancers PD-L1 vs LAG-3 Expression in Non–Small Cell Lung CancerRelate...